Department of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
JAMA Neurol. 2023 Jan 1;80(1):91-98. doi: 10.1001/jamaneurol.2022.3881.
In 2020 during the COVID-19 pandemic, neurologic involvement was common in children and adolescents hospitalized in the United States for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related complications.
To provide an update on the spectrum of SARS-CoV-2-related neurologic involvement among children and adolescents in 2021.
DESIGN, SETTING, AND PARTICIPANTS: Case series investigation of patients reported to public health surveillance hospitalized with SARS-CoV-2-related illness between December 15, 2020, and December 31, 2021, in 55 US hospitals in 31 states with follow-up at hospital discharge. A total of 2253 patients were enrolled during the investigation period. Patients suspected of having multisystem inflammatory syndrome in children (MIS-C) who did not meet criteria (n = 85) were excluded. Patients (<21 years) with positive SARS-CoV-2 test results (reverse transcriptase-polymerase chain reaction and/or antibody) meeting criteria for MIS-C or acute COVID-19 were included in the analysis.
SARS-CoV-2 infection.
Patients with neurologic involvement had acute neurologic signs, symptoms, or diseases on presentation or during hospitalization. Life-threatening neurologic involvement was adjudicated by experts based on clinical and/or neuroradiological features. Type and severity of neurologic involvement, laboratory and imaging data, vaccination status, and hospital discharge outcomes (death or survival with new neurologic deficits).
Of 2168 patients included (58% male; median age, 10.3 years), 1435 (66%) met criteria for MIS-C, and 476 (22%) had documented neurologic involvement. Patients with neurologic involvement vs without were older (median age, 12 vs 10 years) and more frequently had underlying neurologic disorders (107 of 476 [22%] vs 240 of 1692 [14%]). Among those with neurologic involvement, 42 (9%) developed acute SARS-CoV-2-related life-threatening conditions, including central nervous system infection/demyelination (n = 23; 15 with possible/confirmed encephalitis, 6 meningitis, 1 transverse myelitis, 1 nonhemorrhagic leukoencephalopathy), stroke (n = 11), severe encephalopathy (n = 5), acute fulminant cerebral edema (n = 2), and Guillain-Barré syndrome (n = 1). Ten of 42 (24%) survived with new neurologic deficits at discharge and 8 (19%) died. Among patients with life-threatening neurologic conditions, 15 of 16 vaccine-eligible patients (94%) were unvaccinated.
SARS-CoV-2-related neurologic involvement persisted in US children and adolescents hospitalized for COVID-19 or MIS-C in 2021 and was again mostly transient. Central nervous system infection/demyelination accounted for a higher proportion of life-threatening conditions, and most vaccine-eligible patients were unvaccinated. COVID-19 vaccination may prevent some SARS-CoV-2-related neurologic complications and merits further study.
2020 年 COVID-19 大流行期间,美国因严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)相关并发症住院的儿童和青少年中,神经系统受累较为常见。
提供 2021 年美国儿童和青少年与 SARS-CoV-2 相关的神经系统受累的最新情况。
设计、地点和参与者:对 2020 年 12 月 15 日至 2021 年 12 月 31 日期间在 31 个州的 55 家美国医院报告的与 SARS-CoV-2 相关疾病住院的公共卫生监测患者进行病例系列调查,调查期间共纳入 2253 例患者。排除疑似患有儿童多系统炎症综合征(MIS-C)但不符合标准的患者(85 例)。将符合 MIS-C 或急性 COVID-19 标准且 SARS-CoV-2 检测结果阳性(逆转录酶-聚合酶链反应和/或抗体)的年龄<21 岁的患者纳入分析。
SARS-CoV-2 感染。
有神经系统受累的患者在就诊时或住院期间出现急性神经系统体征、症状或疾病。根据临床和/或神经影像学特征,由专家判断是否存在危及生命的神经系统受累。记录神经系统受累的类型和严重程度、实验室和影像学数据、疫苗接种情况以及出院结局(死亡或存活但有新的神经系统缺陷)。
在纳入的 2168 例患者中(58%为男性;中位年龄 10.3 岁),1435 例(66%)符合 MIS-C 标准,476 例(22%)有明确的神经系统受累。有神经系统受累的患者比无神经系统受累的患者年龄更大(中位年龄 12 岁比 10 岁),且更常患有潜在的神经系统疾病(476 例中有 107 例[22%],1692 例中有 240 例[14%])。在有神经系统受累的患者中,42 例(9%)发生急性 SARS-CoV-2 相关危及生命的情况,包括中枢神经系统感染/脱髓鞘(23 例;15 例可能/确诊脑炎,6 例脑膜炎,1 例横贯性脊髓炎,1 例非出血性脑白质病)、中风(11 例)、严重脑病(5 例)、急性暴发性脑水肿(2 例)和格林-巴利综合征(1 例)。10 例(24%)在出院时存活但有新的神经系统缺陷,8 例(19%)死亡。在有危及生命的神经系统疾病的患者中,16 例有疫苗接种资格的患者中有 15 例(94%)未接种疫苗。
2021 年,美国因 COVID-19 或 MIS-C 住院的儿童和青少年中,SARS-CoV-2 相关的神经系统受累持续存在,且再次以短暂性为主。中枢神经系统感染/脱髓鞘占危及生命情况的比例更高,且大多数有疫苗接种资格的患者未接种疫苗。COVID-19 疫苗接种可能预防一些 SARS-CoV-2 相关的神经系统并发症,值得进一步研究。